Eisai co-establishes Global Health Innovative Technology Fund

ntttttttttttt

Eisai Co said Monday it has co-established the Global Health Innovative Technology Fund (GHIT Fund) to advance the research and development of new medicines, vaccines, and diagnostics from Japan to fight infectious diseases in emerging countries and the developing world.

The GHIT Fund is the first public-private partnership in Japan dedicated to the field of global health. It is a partnership between Eisai and four other Japanese pharmaceutical companies, the government of Japan and the Bill & Melinda Gates Foundation. The GHIT Fund will facilitate global partnerships between Japanese and non-Japanese research and development organizations and fund promising research programs in order to realize advances in new health technologies by Japanese pharmaceutical companies, universities and research institutions possessing strengths in drug creation, with the aim of utilizing those technologies effectively in emerging countries and the developing world.

Eisai said it considers this commitment as a long-term investment in its future in an increasingly globalized era and as such consistently engages in initiatives focused on overcoming issues related to access to medicines in order to effectively combat infectious diseases, including neglected tropical diseases (NTDs).

Eisai said it expects the establishment of the GHIT Fund to lead to further global public-private partnerships focused on the development of new drugs and contribute to global health through advances made in new health technologies in Japan.nThe company remains actively committed to continuing the above and other initiatives to ensure access to medicines in emerging countries and the developing world in order to better contribute to increasing the benefits provided to patients and their families in those regions.